Residual disease burden in axSpA and PsA patients who achieved LDA.
| axSpA | PsA | |||
|---|---|---|---|---|
| LDA by ASDAS-ESR < 2.1 | axSpA LDA by BASDAI < 3/10 | LDA by MDA | PsA LDA by cDAPSA | |
| Patients, n (%) | 87 (33.2) | 112 (42.7) | 50 (35.2) | 90 (63.4) |
| Age, yrs | 40.6 (13.7) | 32.8 (12.6) | 53.8 (13.4) | 52.5 (13.2) |
| Women, n (%) | 11 (12.6) | 20 (17.9) | 28 (56.0) | 45 (50.0) |
| Ethnic group, n (%) | ||||
| Chinese | 70 (80.5) | 95 (84.8) | 39 (78.0) | 66 (73.3) |
| Non-Chinese | 17 (19.5) | 17 (15.2) | 11 (22.0) | 24 (26.7) |
| Disease duration, yrs | 8.8 (6.4) | 9.6 (7.9) | 5.5 (5.9) | 5.2 (6.0) |
| BMI, kg/m2 | 24.7 (6.8) | 24.7 (6.4) | 25.7 (5.0) | 26.1 (4.7) |
| TJC (0–68) | 0.1 (0.3) | 0.1 (0.3) | 0.5 (0.7) | 1.0 (1.4) |
| SJC (0–66) | 0.0 (0.2) | 0.0(0.2) | 0.5 (1.0) | 0.9 (1.3) |
| VAS pain (0–100) | 20.8 (16.6) | 21.4 (17.6) | 14.0 (13.8) | 20.8 (16.7) |
| BASDAI (0–10) | 2.3 (1.3) | 1.8 (0.8) | 2.3 (1.5) | 2.7 (1.7) |
| BASDAI fatigue (0–10) | 3.6 (2.5) | 3.2 (2.2) | 3.1 (2.3) | 3.4 (2.3) |
| BASDAI back pain (0–10) | 2.9 (2.3) | 2.2 (1.6) | 1.9 (2.1) | 2.3 (2.1) |
| BASDAI morning stiffness (0–10) | 2.3 (1.8) | 1.9 (1.6) | 2.1 (2.2) | 2.4 (2.3) |
| PtGA (0–100) | 22.7 (16.9) | 24.0 (19.5) | 17.8 (14.8) | 23.5 (17.6) |
| PGA (0–10) | 1.9 (1.2) | 1.6 (1.0) | 1.7 (1.2) | 2.2 (1.5) |
| Dactylitis (0–20) | – | – | 0.2 (0.5) | 0.5 (0.9) |
| LEI (0–6) | – | – | 0.1 (0.3) | 0.2 (0.5) |
| PASI (0–72) | – | – | 1.9 (3.7) | 2.4 (3.8) |
| ESR, mm/h | 8.1 (8.2) | 21.1 (23.2) | 16.3 (13.9) | 18.6 (15.9) |
| HAQ-DI (0–3) | 0.1 (0.3) | 0.1 (0.2) | 0.1 (0.2) | 0.2 (0.4) |
| SF-36 | ||||
| PF (0–100) | 84.1 (16.4) | 84.5 (15.7) | 77.4 (24.4) | 74.5 (24.3) |
| RP (0–100) | 85.3 (17.9) | 84.4 (18.8) | 82.0 (26.2) | 78.5 (25.3) |
| BP (0–100) | 70.0 (16.9) | 70.5 (15.6) | 72.0 (19.0) | 67.7 (18.5) |
| GH (0–100) | 58.1 (20.3) | 58.7 (20.4) | 63.4 (16.0) | 58.8 (17.4) |
| VT (0–100) | 64.0 (16.6) | 64.8 (17.6) | 60.9 (18.4) | 59.6 (17.5) |
| SF (0–100) | 83.3 (17.1) | 82.5 (19.5) | 85.0 (18.0) | 82.9 (19.0) |
| RE (0–100) | 84.2 (19.8) | 85.3 (20.3) | 83.8 (27.2) | 83.5 (24.7) |
| MH (0–100) | 74.3 (16.4) | 74.3 (20.0) | 73.1 (16.9) | 72.8 (17.1) |
| PCS | 47.4 (9.6) | 47.3 (9.2) | 46.6 (12.0) | 45.1 (11.7) |
| MCS | 46.1 (11.6) | 46.5 (12.1) | 46.8 (11.3) | 45.6 (10.6) |
Values expressed in mean (SD) unless specified otherwise. ASDAS-ESR: Ankylosing Spondylitis Disease Activity Score based on erythrocyte sedimentation rate; axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BP: bodily pain; cDAPSA: Clinical Disease Activity in Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; GH: general health; HAQ-DI: Health Assessment Questionnaire-Disability Index; LDA: low disease activity; LEI: Leeds Enthesitis Index; MCS: norm-based mental component summary (mean 50, SD 10); MDA: minimal disease activity; MH: mental health; PASI: Psoriasis Area Severity Index; PCS: norm-based physical component summary (mean 50, SD 10); PF: physical function; PGA: physician global assessment; PsA: psoriatic arthritis; PtGA: patient global assessment; RE: role emotional; RP: role physical; SF: social functioning; SF-36: 36-item Short Form Health Survey; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; VT: vitality.